Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation

Sifei Xing, Cynthia K. Bullen, Neeta S. Shroff, Liang Shan, Hung Chih Yang, Jordyn L. Manucci, Shridhar Bhat, Hao Zhang, Joseph Bernard Margolick, Thomas C Quinn, David M. Margolis, Janet M Siliciano, Robert F Siliciano

Research output: Contribution to journalArticle


Highly active antiretroviral therapy (HAART) can reduce plasma HIV-1 levels to below the detection limit. However, due to the latent reservoir in resting CD4+ cells, HAART is not curative. Elimination of this reservoir is critical to curing HIV-1 infection. Agents that reactivate latent HIV-1 through nonspecific T cell activation are toxic. Here we demonstrate in a primary CD4+ T cell model that the FDA-approved drug disulfiram reactivates latent HIV-1 without global T cell activation. The extent to which disulfiram reactivates latent HIV-1 in patient cells is unclear, but the drug alone or in combination may be useful in future eradication strategies.

Original languageEnglish (US)
Pages (from-to)6060-6064
Number of pages5
JournalJournal of Virology
Issue number12
Publication statusPublished - Jun 2011


ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this